文献速递心脑血管急症

癫痫发作鉴别诊断的新生物标志物:神经颗粒素

A new biomarker in the differential diagnosis of epileptic seizure: Neurogranin.
PubMed 文献 · Am J Emerg Med · 2022-02-06
一句话结论急诊癫痫发作患者血清神经颗粒素中位数184.16 ng/dl,显著高于健康对照97.90 ng/dl(p<0.005),作者认为可考虑用于癫痫发作与PNES的鉴别。

本研究纳入49例因癫痫发作至急诊就诊、经EEG证实的>18岁患者(男19例38.78%、女30例61.22%),对照为53名完全健康志愿者(男28例52.83%、女25例47.17%);排除结构性或感染性脑病(痴呆、卒中、颅内占位、脑膜炎、脑炎、克雅氏病、脓肿等)、颅脑创伤或脓毒症等严重全身性疾病者。患者组血清神经颗粒素中位数184.16 ng/dl(范围110.1-1172.98),对照组97.90 ng/dl(范围73.71-282.11),患者组显著高于对照组(p<0.005)。作者认为血清NRGN在癫痫发作患者中升高,可考虑用于癫痫发作与PNES的鉴别诊断。

要点

  • 癫痫发作急诊患者(n=49)血清神经颗粒素中位数184.16 ng/dl,健康对照(n=53)97.90 ng/dl,患者组显著更高(p<0.005)。
  • 排除结构性或感染性脑病(痴呆、卒中、颅内占位、脑膜炎、脑炎、克雅氏病、脓肿等)及颅脑创伤、脓毒症等严重全身性疾病者。
  • 患者均>18岁且经EEG证实为癫痫发作;对照为完全健康志愿者。
  • 作者认为血清NRGN升高可考虑用于癫痫发作与PNES的鉴别诊断,但原文未报告两组PNES例数及界值。

适用人群与场景

  • >18岁、因癫痫发作至急诊就诊或正在发作、经EEG证实为癫痫发作的患者。
  • 排除结构性或感染性脑病患者(痴呆、卒中、颅内占位、脑膜炎、脑炎、克雅氏病、脓肿等)。
  • 排除颅脑创伤或脓毒症等被认为影响脑血流的严重全身性疾病患者;对照为完全健康志愿者。

研究设计与关键结果

  • 研究共纳入49例患者(男19例38.78%、女30例61.22%)和53名健康对照(男28例52.83%、女25例47.17%)。
  • 患者组血清神经颗粒素中位数184.16 ng/dl(范围110.1-1172.98),对照组97.90 ng/dl(范围73.71-282.11)。
  • 患者组血清神经颗粒素显著高于对照组(p<0.005)。

证据类型、等级与局限

  • 研究类型:病例对照研究(癫痫发作患者 vs 完全健康志愿者)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为血清NRGN在癫痫发作患者中升高,可考虑用于癫痫发作与PNES的鉴别诊断。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

AIM: The aim of this study was to determine the level of serum NGRN in epilepsy patients presenting at the Emergency Department with complaints of an epileptic seizure, and to thus evaluate the utility of this biomarker in the differentiation of epilepsy and PNES patients from each other.

MATERIAL METHODS: The study included patients aged >18 years who had experienced an epileptic seizure or were experiencing an epileptic seizure proven with EEG. All patients with brain disease of structural or infectious cause were excluded from the study (dementia, stroke, intracranial mass, meningitis, encephalitis, Creutzfeldt-Jacobs disease, abscess, etc). Patients were also excluded if they had traumatic brain injury or a severe systemic disease such as sepsis, which was thought to impair brain blood flow. The control group was formed of completely healthy volunteers.

RESULTS: Evaluation was made of a total of 49 patients, comprising 19 (38.78%) males and 30 (61.22%) females, and a control group of 53 healthy volunteers comprising 28 (52.83%) males and 25 (47.17%) females. The serum neurogranin value was median 184.16 ng/dl (range: 110.1-1172.98) in the patient group and 97.90 ng/dl (range: 73.71-282. 11) in the control group. The serum neurogranin value was determined to be statistically significantly higher in the patient group than in the control group (p < 0.005).

CONCLUSION: The differential diagnosis of ES from PNES remains a challenging situation for emergency service physicians. Based on the findings of this study, it can be said that the serum NRGN level is high in patients who have experienced an epileptic seizure. Therefore, this new biomarker can be considered for use in the differential diagnosis of epileptic seizure and PNES.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Kalkan A, Demirel A, Atiş ŞE, et al. A new biomarker in the differential diagnosis of epileptic seizure: Neurogranin. Am J Emerg Med. 2022. PMID: 35152125. doi:10.1016/j.ajem.2022.02.010

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。